Metastasis-directed treatment in kidney cancer.
Journal
Current opinion in urology
ISSN: 1473-6586
Titre abrégé: Curr Opin Urol
Pays: United States
ID NLM: 9200621
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
medline:
3
8
2023
pubmed:
5
7
2023
entrez:
5
7
2023
Statut:
ppublish
Résumé
To provide a critical overview of the latest evidence on the role of metastasis-direct treatment (MDT) in the management of metastatic renal cell carcinoma (mRCC). This is a nonsystematic review of the English language literature published since January 2021. A PubMed/MEDLINE search using various search terms was conducted, including only original studies. After title and abstract screening, selected articles were grouped into two main areas which mirror the main treatment options in this setting: surgical metastasectomy (MS) and stereotactic radiotherapy (SRT). While a limited number of retrospective studies have been reported on surgical MS, the consensus of these reports is that extirpation of metastasis should be part of a multimodal management strategy for carefully selected cases. In contrast, there have been both retrospective studies and a small number of prospective studies on the use of SRT of metastatic sites. As the management of mRCC rapidly evolves, and evidence on MDT - both in the form of MS and SRT - has continued to build over the past 2 years. Overall, there is growing interest in this therapeutic option, which is increasingly being implemented and seems to be safe and potentially beneficial in well selected disease scenarios.
Identifiants
pubmed: 37405715
doi: 10.1097/MOU.0000000000001111
pii: 00042307-990000000-00101
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
375-382Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Di Lorenzo G, Autorino R, Sternberg CN. Metastatic renal cell carcinoma: recent advances in the targeted therapy era. Eur Urol 2009; 56:959–971.
Bedke J, Albiges L, Capitanio U, et al. The 2021 updated European Association of Urology guidelines on renal cell carcinoma: immune checkpoint inhibitor-based combination therapies for treatment-naive metastatic clear-cell renal cell carcinoma are standard of care. Eur Urol 2021; 80:393–397.
Marchioni M, Bandini M, Pompe RS, et al. Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era. Int Urol Nephrol 2017; 49:2143–2149.
Omid S, Abufaraj M, Remzi M. Metastasectomy in patients with renal cell carcinoma: when and how? Curr Opin Urol 2020; 30:602–609.
Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol 2019; 75:799–810.
Motzer RJ, Jonasch E, Agarwal N, et al. Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 2022; 20:71–90.
Lloyd A, Reeves F, Abu-Ghanem Y, Challacombe B. Metastasectomy in renal cellcarcinoma: where are we now? Curr Opin Urol 2022; 32:627–633.
Psutka SP, Master VA. Role of metastasis-directed treatment in kidney cancer. Cancer 2018; 124:3641–3655.
Ishihara H, Takagi T, Kondo T, et al. Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era. Urol Oncol 2021; 39:77.
Meagher MF, Mir MC, Autorino R, et al. Impact of metastasectomy on cancer specific and overall survival in metastatic renal cell carcinoma: analysis of the REMARCC Registry. Clin Genitourin Cancer 2022; 20:326–333.
Stühler V, Herrmann L, Maas M, et al. Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies. World J Urol 2022; 40:1175–1183.
Choueiri TK, Tomczak P, Park SH, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med 2021; 385:683–694.
Maisel F, Smolle MA, Mollnar S, et al. Benefit of metastasectomy in renal cell carcinoma: a propensity score analysis. Clin Genitourin Cancer 2022; 20:344–353.
Meyer CP, Sun M, Karam JA, et al. Complications after metastasectomy for renal cell carcinoma—a population-based assessment. Eur Urol 2017; 72:171–174.
Lyon TD, Roussel E, Sharma V, et al. International multiinstitutional characterization of the perioperative morbidity of metastasectomy for renal cell carcinoma. Eur Urol Oncol 2023; 6:76–83.
Blanco-Fernández G, Fondevila-Campo C, Sanjuanbenito A, et al. Pancreatic metastases from renal cell carcinoma. Postoperative outcome after surgical treatment in a Spanish multicenter study (PANMEKID). Eur J Surg Oncol 2022; 48:133–141.
Liu Y, Long W, Zhang Z, et al. Metastasis-directed stereotactic body radiotherapy for oligometastatic renal cell carcinoma: extent of tumor burden eradicated by radiotherapy. World J Urol 2021; 39:4183–4190.
Stewart GA, Breen WG, Stish BJ, et al. Thoracic radiotherapy for renal cell carcinoma metastases: local control for the management of lung and mediastinal disease in the modern era. Clin Genitourin Cancer 2022; 20:107–113.
Marvaso G, Corrao G, Oneta O, et al. Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how? Clin Transl Oncol 2021; 23:1717–1726.
Onal C, Hurmuz P, Guler OC, et al. The role of stereotactic body radiotherapy in switching systemic therapy for patients with extracranial oligometastatic renal cell carcinoma. Clin Transl Oncol 2022; 24:1533–1541.
Onal C, Guler OC, Hurmuz P, et al. Bone-only oligometastatic renal cell carcinoma patients treated with stereotactic body radiotherapy: a multiinstitutional study. Strahlenther Onkol 2022; 198:940–948.
Franzese C, Marini B, Baldaccini D, et al. The impact of stereotactic ablative radiotherapy on oligoprogressive metastases from renal cell carcinoma. J Cancer Res Clin Oncol 2022; doi: 10.1007/s00432-022-04352-z.
doi: 10.1007/s00432-022-04352-z
De B, Venkatesan AM, Msaouel P, et al. Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. BJU Int 2022; 129:610–620.
Schoenhals JE, Mohamad O, Christie A, et al. Stereotactic ablative radiation therapy for oligoprogressive renal cell carcinoma. Adv Radiat Oncol 2021; 6:100692.
Ma MW, Li HZ, Gao XS, et al. Outcomes of high-dose stereotactic ablative radiotherapy to all/multiple sites for oligometastatic renal cell cancer patients. Curr Oncol 2022; 29:7832–7841.
Franzese C, Marvaso G, Francolini G, et al. The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group. Clin Exp Metastasis 2021; 38:527–537.
Cheung P, Patel S, North SA, Sahgal A, et al. Stereotactic radiotherapy for oligoprogression in metastatic renal cell cancer patients receiving tyrosine kinase inhibitor therapy: a phase 2 prospective multicenter study. Eur Urol 2021; 80:693–700.
Hannan R, Christensen M, Hammers H, et al. Phase II trial of stereotactic ablative radiation for oligoprogressive metastatic kidney cancer. Eur Urol Oncol 2022; 5:216–224.
Hannan R, Christensen M, Christie A, et al. Stereotactic ablative radiation for systemic therapy-naïve oligometastatic kidney cancer. Eur Urol Oncol 2022; 5:695–703.
Siva S, Bressel M, Wood ST, et al. Stereotactic radiotherapy and short-course pembrolizumab for oligometastatic renal cell carcinoma—the RAPPORT Trial. Eur Urol 2022; 81:364–372.
Masini C, Iotti C, De Giorgi U, et al. Nivolumab in combination with stereotactic body radiotherapy in pretreated patients with metastatic renal cell carcinoma. Results of the phase II NIVES study. Eur Urol 2022; 81:274–282.